Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J. bras. med ; 92(3): 31-35, mar. 2007.
Article in Portuguese | LILACS | ID: lil-458471

ABSTRACT

Esclerose sistêmica ou esclerodermia é uma doença do tecido conectivo de causa desconhecida que se caracteriza por fibrose de pele, dos vasos sangüíneos e dos órgãos viscerais, incluindo trato gastrintestinal, pulmões, coração e rins. As manifestações pulmonares são as principais causas de morte, sendo a hipertensão pulmonar uma delas. Ela é caracterizada por um aumento progressivo da pressão arterial pulmonar (>30mmHg) e da resistência vascular, levando, geralmente, à falência ventricular direita e morte. Com esta revisão pôde se verificar o que se tem feito para inibir a progressão das manifestações pulmonares da esclerodermia com o uso judicioso de novas estratégias clínicas e cirúrgicas


Subject(s)
Humans , Scleroderma, Systemic/complications , Scleroderma, Systemic/physiopathology , Scleroderma, Systemic/therapy , Hypertension, Pulmonary/physiopathology , Hypertension, Pulmonary/therapy , Calcium Channel Blockers , Epoprostenol , Iloprost , Calcitonin Gene-Related Peptide/therapeutic use
2.
Ceylon Med J ; 1998 Sep; 43(3): 138-46
Article in English | IMSEAR | ID: sea-47455

ABSTRACT

OBJECTIVE: Pre-eclamptic toxemia (PET) affects 4 to 8% of human pregnancies. Presently, reliable specific therapies to treat this disorder are not available. This study was designed to develop a new therapeutic approach in the management of PET using an animal model. DESIGN: Pregnant rats (5/group) infused with 50 mg L-NAME daily via osmotic mini pumps from day 17 of gestation developed a PET-like syndrome. Systolic blood pressure (BP) was monitored daily during pregnancy and up to 7 days postpartum by the tail cuff method. Pup weight and mortality were recorded immediately after delivery. We examined the effect of CGRP to ameliorate L-NAME-induced hypertension during pregnancy, and the efficacy of CGRP and progesterone in combination to inhibit L-NAME-induced hypertension during the post-partum period. RESULTS: Blood pressure in L-NAME-treated rats was significantly elevated (P < 0.01) throughout pregnancy (141 +/- 3 to 166 +/- 10 mm Hg). CGRP 10 micrograms/day did not cause hypotension, the values being similar to controls which received only saline. On the other hand, CGRP infusion inhibited L-NAME-induced hypertension to normotensive levels (116 +/- 3 to 122 +/- 2) during pregnancy (up to day 22 of gestation), but not during postpartum period (137 +/- 8 to 148 +/- 2). During the post-partum period, neither progesterone nor CGRP by itself was effective in lowering L-NAME-induced hypertension. The combination of CGRP with progesterone decreased BP to control levels in the post-partum period, and also significantly improved foetal mortality and growth (P < 0.05). CONCLUSIONS: CGRP inhibited L-NAME-induced hypertension during pregnancy and not during postpartum period. The same phenomenon was evident in the presence of adequate levels of progesterone in the post-partum period. We believe that CGRP regulates vascular adaptations during pregnancy and these effects may be progesterone-dependent. This combination treatment of CGRP plus progesterone may be a promising therapy in the management of PET in humans.


Subject(s)
Animals , Blood Pressure/drug effects , Calcitonin Gene-Related Peptide/therapeutic use , Disease Models, Animal , Drug Therapy, Combination , Embryonic and Fetal Development/drug effects , Female , Hemodynamics , Hypertension/chemically induced , NG-Nitroarginine Methyl Ester , Postpartum Period/drug effects , Pre-Eclampsia/chemically induced , Pregnancy , Progesterone/therapeutic use , Rats , Rats, Sprague-Dawley , Survival Rate
3.
Rev. Inst. Méd. Sucre ; 41(105): 10-7, feb. 1995. tab
Article in Spanish | LILACS | ID: lil-174610

ABSTRACT

La concentracion plasmatica del peptido natriuretico auricular se encuentra elevada en los ancianos y si son hipertensos, sus valores son mucho mas altos. Con el obejto de estudiar el peptido natriuretico auricular y la respuesta del sistema angiotensina aldosterona, se le administro un suplemento de calcio oral a un grupo de ancianos hipertensos y a otro grupo de normotensos, que nos sirvio de control. Se seleccionaron 22 ancianos hipertensos (2 hombres y 20 mujeres), con una edad de 75 +/- años y 10 ancianos normotensos (2 hombres y 8 mujeres) con igual promedio de edad. Se le practicaron tomas tensionales con esfignomanometro de Hg en 3 posiciones (de cubito, sentado y de pie). Por el metodo de radioinmunoensayo se les dosificaron el peptido natriuretico auricular, de actividad de la renian plasmatica, la aldosterona plasmatica por absorcion atomica se le determino el calcio serico total, antes y despues de recibir 1.5 g/dia de CaCO3, por un periodo de 4 semanas. En los hipertensos se obtuvieron los siguientes resultados: el peptido natriuretico auricular descendio de manera imporatante (P<0.001), en igual forma lo hizo la aldosterona (P<0.001), por el contrario la reina (P<0.001) y el Calcio (P<0.001) aumentaron sus valores. Igualmente se consiguieron las correlaciones inversas entre renina/peptido y entre peptido/calcio, pero no se observo esta relacion entre aldosterona/peptido. En los acnianos normotensos, se obtuvo un descenso del peptido (P<,05) y un incremento del calcio serico total (P<0,05). En los hipertensos descendieron sus cifras tensionales sistolica (P<0.001) y las distolicas (P<0,05). Estos resultados ponene en evidencia las relaciones tan estrecha que existen entre la tension arterial (especialmente la sistolica, peptido, renina, aldosterona, calcio serico en ancianos hipertensos y menos significativos en los normotensos. En conclusion la administracion de calcio oral a ancianos, especialmente hipertensos, determino en ellos una serie de cambios en los grupos hormonales que manejan la homeostasis agua-sodio. Esta accion se ejerce probablemente de manera indirecta, yaque al actuar como hipotensor, se van a corregir lasalteraciones antes mencionadas en los dos grupos hormonales que intervienen en este equilibrio.


Subject(s)
Humans , Male , Female , Aged , Calcitonin Gene-Related Peptide/therapeutic use , Renin/administration & dosage , Aldosterone/metabolism , Bolivia , Calcium/administration & dosage , Hypertension/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL